Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
46 participants
INTERVENTIONAL
1997-11-30
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized phase I trial is studying the side effects and best dose of cytomegalovirus vaccine in healthy participants.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To establish whether 4 dose levels of the CMVpp65-A\*0201 peptide vaccine are safe and well tolerated in cytomegalovirus (CMV)-seropositive participants.
* To determine whether the CMVpp65-A\*0201 peptide vaccine, when given as a single injection followed by one booster injection at a safe and well-tolerated dose, is capable of stimulating a memory response in CMV-seropositive participants.
* To evaluate whether CMV-seronegative participants generate a de novo immune response against CMV after immunization with CMVpp65-A\*0201 peptide vaccine given as a single injection followed by three booster injections.
* To determine the duration of immune enhancement of CMV-specific cytotoxic T-lymphocyte function as assessed for up to 12 months after primary or secondary immunization with the CMVpp65-A\*0201 peptide vaccine.
OUTLINE: This is a dose-escalation study of CMVpp65-A\*0201 peptide vaccine in cytomegalovirus (CMV)-seropositive participants. Once a safe dose is established, CMV-seronegative participants are accrued and immunized at that dose. Participants are stratified according to gender.
* CMV-seropositive participants: Participants are randomized to receive 1 of 4 escalating doses of CMVpp65-A\*0201 peptide vaccine containing either helper T-lymphocyte (HTL) PADRE peptide or HTL tetanus toxoid peptide. Within each vaccine dose group, two participants are randomized to receive a placebo. Participants receive the vaccine or a placebo subcutaneously (SC) on days 0 and 28 in the absence of unacceptable toxicity.
* CMV-seronegative participants: Participants are randomized to receive 1 of 4 established doses (established in CMV-seropositive participants) of CMVpp65-A\*0201 peptide vaccine containing either HTL PADRE peptide or HTL tetanus toxoid peptide. Participants receive the vaccine on days 0, 28, and 56 in the absence of unacceptable toxicity. Participants with a partial or low-level immune response receive one additional booster vaccine on day 90.
Participants undergo blood sample collection at baseline and periodically during study for immunologic laboratory studies. Participants also undergo skin biopsy at baseline. Laboratory studies include assessment of human cytotoxic T-lymphocyte activity and response by \^51chromium-release assay, limiting-dilution analysis, and T-cell proliferation assay; and CD4/CD8 phenotyping by FACScan® flow cytometry.
After completion of study therapy, participants are followed for 12 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CMV-seropositive participants
Participants are randomized to receive 1 of 4 escalating doses of CMVpp65-A\*0201 peptide vaccine containing either helper T-lymphocyte (HTL) PADRE peptide or HTL tetanus toxoid peptide. Within each vaccine dose group, two participants are randomized to receive a placebo. Participants receive the vaccine or a placebo subcutaneously (SC) on days 0 and 28 in the absence of unacceptable toxicity.
CMVpp65-A*0201 peptide vaccine
Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
CMV-seronegative participants
Participants are randomized to receive 1 of 4 established doses (established in CMV-seropositive participants) of CMVpp65-A\*0201 peptide vaccine containing either HTL PADRE peptide or HTL tetanus toxoid peptide. Participants receive the vaccine on days 0, 28, and 56 in the absence of unacceptable toxicity. Participants with a partial or low-level immune response receive one additional booster vaccine on day 90.
CMVpp65-A*0201 peptide vaccine
Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CMVpp65-A*0201 peptide vaccine
Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy participant
* Cytomegalovirus seropositive or seronegative
* HLA-A\*0201-positive
PATIENT CHARACTERISTICS:
* CBC within 1.5 times normal
* SMA-18 within 1.5 times normal
* Hepatitis B virus antigen seronegative
* Hepatitis C virus seronegative
* No diagnosis that is associated with immunodeficiency, including HIV infection
* No serious abnormalities by EKG (in participants ≥ 50 years of age)
* Not pregnant
PRIOR CONCURRENT THERAPY:
* More than 6 months since prior surgery
* No concurrent daily medications for chronic or current illness, except for the following:
* Thyroid replacement therapy
* Estrogen replacement therapy
* Dietary vitamins and protein supplements
* Antihistamine medication
* Anticholesterol medication
* Cardiac and antihypertensive medication
* Any medication, as determined by the principal investigator, that is not known or likely to be immunosuppressive
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
City of Hope Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
City of Hope Comprehensive Cancer Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Don Diamond, PhD
Role: PRINCIPAL_INVESTIGATOR
City of Hope Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHNMC-97092
Identifier Type: -
Identifier Source: secondary_id
CDR0000599675
Identifier Type: -
Identifier Source: org_study_id